Form 8-K - Current report:
SEC Accession No. 0001641172-25-014895
Filing Date
2025-06-12
Accepted
2025-06-12 16:47:15
Documents
13
Period of Report
2025-06-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 59643
2 EX-10.1 ex10-1.htm EX-10.1 158944
  Complete submission text file 0001641172-25-014895.txt   422267

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE zvsa-20250611.xsd EX-101.SCH 3011
4 XBRL LABEL FILE zvsa-20250611_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE zvsa-20250611_pre.xml EX-101.PRE 22356
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3855
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41184 | Film No.: 251043531
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)